CVS Q1 2026: Improvement Validates Undervaluation Thesis

What happened

CVS Health reported Q1 2026 results with 6.2% revenue growth and a 63.1% EPS increase, prompting management to raise full-year guidance for revenue, cash flow, and earnings. Early signs of margin recovery and an improving medical benefit ratio support the view that elevated Medicare utilization in 2024 is stabilizing, as anticipated in our earlier analysis. The company's transformation towards transparent pricing and cost restructuring is gaining traction, with raised 2025 adjusted EPS guidance now at ~$6.30–$6.40. Despite lingering regulatory and litigation overhangs, this quarter's performance strengthens the case that CVS remains deeply undervalued at ~12x trailing earnings. The integrated payer-PBM-pharmacy platform is beginning to deliver on its long-term margin potential.

Implication

The strong Q1 2026 results, with 63.1% EPS growth and raised full-year guidance, confirm that the operational turnaround is underway. Investors should expect continued margin recovery as restructuring savings and transparent pricing models gain traction. However, PBM regulation and litigation remain key risks that could disrupt the trajectory. The raised 2025 adjusted EPS guidance of $6.30–$6.40 provides a clear near-term anchor, implying a P/E below 13x at current prices. A disciplined entry point remains attractive, but position sizing should account for regulatory uncertainty.

Thesis delta

The Q1 2026 report provides concrete evidence that the medical benefit ratio is improving and margins are recovering, shifting the thesis from a hope of stabilization to confirmation of improvement. This reduces the risk of downside from Medicare utilization and supports the BUY stance with increased conviction. The key watch items from the prior report—Medicare utilization, PBM regulation, and restructuring execution—now show positive signals on utilization and restructuring, while regulatory risk persists.